AlphAIAlphAI — Financial news for AI agents
GlobeNewswireNOV 183 min read$IVVD

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

NEW HAVEN, Conn., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Invivyd, Inc. ( Invivyd ) ( Nasdaq: IVVD ) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, ...

Original reporting
GlobeNewswire · Invivyd
Published Nov 18, 2025, 3:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2025, 4:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$IVVDNeutralMed
01

Why it matters

While immediate share dilution may pressure the stock price, the infusion of capital could support future growth and innovation.

02

Market read

The news is highly relevant to biotech investors and traders focusing on company-specific catalysts.

03

What to watch

Market's overall risk appetite and broader biotech sector trends could influence Invivyd's stock response beyond the offering details.

Relevance 6/10Timing: High, as the news was published shortly after the offering was priced.

Background

Invivyd's recent capital raise aims to fund research and development, expand clinical trials, or strengthen its balance sheet.

Company-level read

Ticker impact

$IVVDNeutralMedium confidence
Context

The news pertains directly to Invivyd's capital raising activities, which can influence its stock price.

Expected impact

Potential short-term price decline due to dilution concerns; long-term impact depends on use of proceeds.

Evidence & confidence

Equity offerings often lead to immediate dilution, but the overall impact depends on investor perception and company fundamentals.

Market effects

Sector

Potential impact on biotech and pharmaceutical sectors due to capital raising activities.

Regional

Limited regional impact; primarily affects U.S.-based biotech stocks.

Global

Moderate, as biotech sector is globally interconnected, but specific to Invivyd.

Counterpoint

What could challenge this read

The capital raise could be viewed positively if investors believe it will fund promising growth initiatives, leading to long-term share appreciation.

Key entities

  • Company
    Invivyd, Inc.

    Biotech firm focused on infectious disease therapeutics.

Read at source← All news

Related articles

OCT 21
$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

investing.com2 min
OCT 21
$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

tradingview.com1 min
OCT 21
$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.

stocktitan.net2 min
OCT 14
$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

investing.com1 min
OCT 14
$IVVDMedAI 8/10

Invivyd, Inc. (IVVD) Begins Phase 2 Trial of VYD2311 for Long COVID/PVS

Invivyd, Inc. (IVVD) has initiated a Phase 2 trial, FLINTLOCK, to evaluate the safety and efficacy of VYD2311, a monoclonal antibody, in treating Long COVID and Post-Vaccination Syndrome. The trial involves ~130 participants and will assess high-dose VYD2311 against a placebo over 90 days. VYD2311 has shown strong antiviral potency against SARS-CoV-2 variants. Success could open a new treatment market, addressing a significant unmet need.

tradingview.com1 min
OCT 14
$IVVDMedAI 8/10

Millions live with long COVID. A trial will test an antibody as a possible treatment.

Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.

stocktitan.net2 min